Characterization of Aspirated Duodenal Fluids from Parkinson's Disease Patients.
Parkinson’s disease
clinical study
drug absorption
duodenal fluid composition
gastrointestinal fluid aspiration
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
14 Apr 2023
14 Apr 2023
Historique:
received:
10
02
2023
revised:
16
03
2023
accepted:
05
04
2023
medline:
28
4
2023
pubmed:
28
4
2023
entrez:
28
4
2023
Statut:
epublish
Résumé
Parkinson's disease, one of the most common neurodegenerative diseases, may not only affect the motor system, but also the physiology of the gastrointestinal tract. Delayed gastric emptying, impaired motility and altered intestinal bacteria are well-established consequences of the disease, which can have a pronounced effect on the absorption of orally administered drugs. In contrast, no studies have been performed into the composition of intestinal fluids. It is not unlikely that Parkinson's disease also affects the composition of intestinal fluids, a critical factor in the in vitro and in silico simulation of drug dissolution, solubilization and absorption. In the current study, duodenal fluids were aspirated from Parkinson's disease (PD) patients and age-matched healthy controls (healthy controls, HC) consecutively in fasted and fed conditions. The fluids were then characterized for pH, buffer capacity, osmolality, total protein, phospholipids, bile salts, cholesterol and lipids. In a fasted state, the intestinal fluid composition was highly similar in PD patients and healthy controls. In general, the same was true for fed-state fluids, apart from a slightly slower and less pronounced initial change in factors directly affected by the meal (i.e., buffer capacity, osmolality, total protein and lipids) in PD patients. The absence of a fast initial increase for these factors immediately after meal intake, as was observed in healthy controls, might result from slower gastric emptying in PD patients. Irrespective of the prandial state, a higher relative amount of secondary bile salts was observed in PD patients, potentially indicating altered intestinal bacterial metabolism. Overall, the data from this study indicate that only minor disease-specific adjustments in small intestinal fluid composition should be considered when simulating intestinal drug absorption in PD patients.
Identifiants
pubmed: 37111729
pii: pharmaceutics15041243
doi: 10.3390/pharmaceutics15041243
pmc: PMC10145225
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : KU Leuven
ID : C24/17/076
Organisme : Research Foundation - Flanders
ID : 1830517N
Organisme : UCB Biopharma SPRL
ID : NA
Références
Neurology. 1967 May;17(5):427-42
pubmed: 6067254
J Neural Transm (Vienna). 2003 May;110(5):517-36
pubmed: 12721813
Parkinsonism Relat Disord. 2020 Jul;76:63-71
pubmed: 32461054
Mov Disord. 2001 Nov;16(6):1041-7
pubmed: 11748735
Adv Drug Deliv Rev. 2007 Jul 30;59(7):591-602
pubmed: 17599644
J Pharm Sci. 2014 Nov;103(11):3398-3411
pubmed: 25277073
Anal Chem. 2015 Apr 21;87(8):4110-6
pubmed: 25837572
Eur J Pharm Sci. 2021 Jul 1;162:105812
pubmed: 33753215
Eur J Pharm Sci. 2014 Jun 16;57:322-32
pubmed: 23994640
Eur J Pharm Sci. 2014 Oct 15;63:178-86
pubmed: 25063035
Drug Discov Today. 2019 Feb;24(2):417-427
pubmed: 30453059
Mol Pharm. 2017 Apr 3;14(4):1251-1263
pubmed: 28186768
Nat Rev Neurol. 2022 Aug;18(8):476-495
pubmed: 35750883
Eur J Pharm Sci. 2020 Apr 30;147:105280
pubmed: 32109493
Eur J Pharm Biopharm. 2021 Jun;163:240-251
pubmed: 33872761
J Neurol Neurosurg Psychiatry. 1988 Jun;51(6):745-52
pubmed: 2841426
Int J Pharm. 2017 Nov 25;533(1):298-314
pubmed: 28870765
Neurosci Lett. 2006 Mar 20;396(1):67-72
pubmed: 16330147
Mol Pharm. 2017 Dec 4;14(12):4281-4294
pubmed: 28737409
Neurogastroenterol Motil. 2006 May;18(5):369-75
pubmed: 16629864
Eur J Pharm Sci. 2010 Jan 31;39(1-3):15-22
pubmed: 19837159
Gut. 1999 May;44(5):598-602
pubmed: 10205192
Parkinsons Dis. 2016;2016:6762528
pubmed: 28050310
AAPS J. 2020 May 26;22(4):78
pubmed: 32458089
Parkinsons Dis. 2013;2013:742128
pubmed: 23476890
J Pharm Sci. 2016 Feb;105(2):673-681
pubmed: 26228456
NPJ Parkinsons Dis. 2022 Mar 24;8(1):31
pubmed: 35332158
Eur J Pharm Biopharm. 2019 Mar;136:70-83
pubmed: 30579851
Brain Sci. 2021 Jun 23;11(7):
pubmed: 34201699
Adv Drug Deliv Rev. 2021 Apr;171:289-331
pubmed: 33610694
Pharmacol Res. 2018 Jul;133:170-186
pubmed: 29660405
Mov Disord. 2004 Nov;19(11):1306-12
pubmed: 15390007
J Pers Med. 2022 Jan 05;12(1):
pubmed: 35055364
J Parkinsons Dis. 2020;10(4):1699-1707
pubmed: 32804102
Adv Drug Deliv Rev. 2022 Feb;181:114084
pubmed: 34929252